Heron Therapeutics (HRTX) Approval 'Positive, Even Without The Cherry on Top' - Cantor Fitzgerald
Tweet Send to a Friend
Cantor Fitzgerald analyst Brandon Folkes reiterated an Overweight rating and $26.00 price target on Heron Therapeutics (NASDAQ: HRTX) following FDA ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
